The Age of Disease Modification in Alzheimer’s Disease: A Grand Rounds Series on the Practical Implementation of Amyloid Targeting Therapies into Clinical Practice

June 19, 2025

Program Description

Target Audience

This program is intended for neurologists, geriatricians, geriatrics psychiatrists, advanced practice providers (APPs), and other health professionals involved in the care of patients with mild cognitive impairment and early AD.This program is intended for neurologists, geriatricians, geriatrics psychiatrists, advanced practice providers (APPs), and other health professionals involved in the care of patients with mild cognitive impairment and early AD.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Review current recommendations/best practices to identify and counsel individuals eligible for new and emerging DMTs anti-Aβ mAbs
  • Evaluate the safety, efficacy, and administration/monitoring requirements of approved and emerging anti-Aβ mAbs to optimize treatment selection and long-term use for eligible patients
  • Appraise the identification and management strategies for ARIA to prepare for timely recognition of and effective response to these events
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
Course opens: 
06/03/2025
Course expires: 
06/26/2025
Event starts: 
06/19/2025 - 8:00am EDT
Event ends: 
06/19/2025 - 9:00am EDT
Cost:
$0.00
Add to calendar: 
Rating: 
0

UPDATE

UPDATE

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

Price

Cost:
$0.00
Please login or register to take this course.